Atrium Therapeutics, Inc.
RNAHealthcare|Biotechnology|US
$8.34
+0.02 (+0.24%)
Tangible Book / Share
$12.54
Cash / Share
$15.45
About
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Stock Price
-43.5%(1Y)
1M
+1.0%
3M
-32.4%
6M
-36.2%
YTD
-43.5%
1Y
-43.5%
3Y
-43.5%
5Y
-43.5%
Pipeline Summary
93 total trials3
Phase 1
11
Phase 2
6
Phase 3
2
Phase 4
Completed: 31Terminated: 7Unknown: 7Recruiting: 30Active: 11Not Yet Recruiting: 4Withdrawn: 3
Active Trials (41)
Comprehensive Care for AYA: Needs Assessment Survey
NCT07196241Cancer
Recruiting
Enrollment: 300 participants
LCI-PED-NOS-EXER-001: Exercise in Pediatric Oncology Patients
NCT05058508Pediatric Cancer
N/ARecruiting
Enrollment: 60 participants
ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
NCT06945042Acute Myeloid Leukemia
N/ARecruiting
Enrollment: 120 participants
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
NCT03141359Lung Cancer Stage II
Phase 2Active
Enrollment: 61 participants
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
NCT02942355Female Breast Carcinoma
Phase 2Active
Enrollment: 40 participants
Key Facts
Market Cap$142.7M
Employees511
CEOKathleen Gallagher
IPO DateFeb 27, 2026
Beta0.37
52-Week Range$7.49 – $16.77
Avg Volume249,668
ExchangeNASDAQ
Websiteatriumtherapeutics.com
Ownership
Float87.9%
Shares Outstanding17.1M
Recent Insider Trades
Younis HusamTAX W/H
Sep 18, 202611,216 shares @ $8.95
Hughes Steven GeorgeTAX W/H
Sep 18, 202621,459 shares @ $8.95
Flanagan W. MichaelTAX W/H
Sep 18, 202622,812 shares @ $8.95
Boyce SarahTAX W/H
Sep 18, 2026126,418 shares @ $8.95
Kenney StephanieTAX W/H
Sep 18, 20262,375 shares @ $8.95
Recent News
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
Nov 2, 2026 · prnewswire.com
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
Oct 27, 2026 · prnewswire.com
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Oct 20, 2026 · prnewswire.com
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
Oct 20, 2026 · prnewswire.com
Atrium Therapeutics (NASDAQ: RNA) lines up $50 million private placement
Oct 10, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:32 AM